All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Which actionable mutations in MM are the MMRF testing in their MyDrug initiative?

During the European School of Haematology (ESH) 3rd How to Diagnose and Treat Multiple Myeloma conference, the Multiple Myeloma Hub spoke to Daniel Auclair, Multiple Myeloma Research Foundation (MMRF), Norwalk, US. We asked, Which actionable mutations in MM are the MMRF testing in their MyDrug initiative?

Which actionable mutations in MM are the MMRF testing in their MyDrug initiative?

Historically, therapeutic agents used in multiple myeloma (MM) were targeting the plasma cell biology of the disease. The MyDrug protocol, developed by the MMRF, is exploring the alternatives. In this video, Auclair discusses precision medicine and the use of agents targeting specific gene alterations in individual patients with MM.

Share: